Zobrazeno 1 - 10
of 67
pro vyhledávání: ''
Autor:
Yanyan Cao, Tao Sun, Xiaopeng Guo, Tao Ouyang, Xuefeng Kan, Lei Chen, Bin Liang, Mingfu Wang, Chuansheng Zheng
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
ObjectiveTo compare the efficacy and safety of transarterial chemoembolization (TACE) combining with sorafenib or apatinib for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).MethodsFrom June 2015 to March 2020, a tot
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Frontiers in Genetics
Frontiers in Genetics
BackgroundProstate cancer (PCa) is among the leading causes of cancer mortality. Dicycloplatin is a newer generation platinum-based drug that has less side effects than cisplatin and carboplatin. However, its effects in PCa is mixed due to lack of ap
Autor:
Fuyin Le, Lilan Yang, Yiwen Han, Yanying Zhong, Fuliang Zhan, Ying Feng, Hui Hu, Tingtao Chen, Buzhen Tan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Chemoresistance is the primary reason for the poor prognosis of patients with ovarian cancer, and the search for a novel drug treatment or adjuvant chemotherapy drug is an urgent need. The tumor microenvironment plays key role in the incidence and de
Autor:
Alexia Vereertbrugghen, Ana Colado, Ernesto Gargiulo, Raimundo Fernando Bezares, Horacio Fernández Grecco, Gregorio Cordini, Maria del Rosario Custidiano, Jean-Hugues François, Guy Berchem, Mercedes Borge, Jerome Paggetti, Etienne Moussay, Romina Gamberale, Mirta Giordano, Pablo Elías Morande
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Current standard treatment of patients with hairy cell leukemia (HCL), a chronic B-cell neoplasia of low incidence that affects the elderly, is based on the administration of purine analogs such as cladribine. This chemotherapy approach shows satisfa
Autor:
Rakesh Popat, Jonathan Carmichael, Gabriel Wallis, Kwee Yong, Christopher Parrish, Catherine S. Y. Lecat, Xenofon Papanikolaou, Neil Rabin, Shameem Mahmood, Jonathan Sive, Lydia Lee, Ashutosh D. Wechalekar, Jessica B Taube, Charalampia Kyriakou, William R. Wilson, Gordon Cook
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundThe treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now represent a chal
Autor:
Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundTrastuzumab shows excellent benefits for HER2+ breast cancer patients, although 20% treated remain unresponsive. We conducted a retrospective cohort study to optimize neoadjuvant chemotherapy and trastuzumab treatment in HER2+ breast cancer
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and mortality, is a common and well-known complication that occurs during the treatment of non-Hodgkin lymphoma (NHL) patients with current or past exposure to HBV infect
Autor:
Guido Carillio, Gerardo Botti, Giacomo Pascarella, Carmine La Manna, Giuliano Palumbo, Maria Carmela Piccirillo, Nicola Normanno, Agnese Montanino, Vincenzo Sforza, Alessandro Morabito, Anna Manzo, Priscilla Cascetta, Claudia Sandomenico, Raffaele Costanzo, Giovanna Esposito
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
The standard third-line treatment of metastatic colorectal cancer (mCRC) includes the small-molecule anti-vascular drugs (Regofenib and Fruquintinib) and the chemotherapy drug trifluridine and tipiracil hydrochloride (TAS-102). There is no standard t
Autor:
Adél Kárpáti, Mihály Cserepes, László Őrfi, Györgyi A. Nelhűbel, Zita Hegedűs, József Tóvári, Erzsébet Rásó, Judit Dobos, Bálint Szokol, Tamás Barbai, Balázs Szabó, Dóra Türk, Viktoria Laszlo, István Kenessey
Publikováno v:
Pathology and Oncology Research
Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although seve